In this video, Donald J. D’Amico, MD, discusses data from the phase 2 LUNA trial of Ixo-vec intravitreal gene therapy for neovascular age-related macular degeneration.
The results, presented at the American Society of Retina Specialists annual meeting, showed that after 26 weeks, the frequency of additional annualized anti-VEGF injections was reduced by more than 90%.
“Of course, there is a need to evaluate these patients carefully for either supplemental regular anti-VEGF injections if they show signs of worsening and/or secondary inflammatory events,” D’Amico,